Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures (IR)

An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures

The purpose of this Phase III study is to evaluate the efficacy, safety and tolerability and health outcomes of retigabine Immediate Release (IR) as adjunctive therapy to each of the following monotherapy Antiepileptic Drug (AED) treatments: carbamazepine/oxcarbazepine, lamotrigine, levetiracetam, or valproic acid in adult subjects with partial-onset seizures (POS) using a flexible dosing regimen.

Study Overview

• Status: Completed
• Conditions: Epilepsy
• Intervention / Treatment: Drug: Retigabine IR

Detailed Description

This is an open-label, multi-centre, flexible dose study of retigabine immediate release (IR). The study will enroll male and female outpatients (≥ 18 years of age) with partial-onset seizures (POS) who are inadequately controlled on their current monotherapy Antiepileptic Drug (AED). Following a Screening Period of up to 2 weeks, subjects will enter an 8-week Baseline Phase to determine baseline seizure frequency. At the end of the Baseline Phase, subjects who meet or exceed the minimum seizure frequency of 4 partial seizures per 56 days, will enter the Treatment Period (4 weeks Titration, 16 weeks Flexible Dose Evaluation Phase). All subjects will receive retigabine IR starting at 150 mg/day and will be titrated to 600 mg/day by Week 4. From Week 5 onwards, subjects' doses will be maintained between 300 to 1200 mg/day using a flexible dosing regimen to optimise response and tolerability. The maximum duration of the study is approximately 33 weeks (inclusive of a 3 week Taper/Follow-up Phase).

• Study Type: Interventional
• Enrollment (Actual): 203
• Phase: Phase 3

Contacts and Locations

Study Locations

• Belgium
  • Gent, Belgium, 9000
    • GSK Investigational Site
  • Leuven, Belgium, 3000
    • GSK Investigational Site
  • Liège, Belgium, 4000
    • GSK Investigational Site
• Bulgaria
  • Pleven, Bulgaria, 5800
    • GSK Investigational Site
  • Plovdiv, Bulgaria, 4000
    • GSK Investigational Site
  • Sofia, Bulgaria, 1431
    • GSK Investigational Site
  • Sofia, Bulgaria, 1113
    • GSK Investigational Site
• Denmark
  • Dianalund, Denmark, 4293
    • GSK Investigational Site
  • Glostrup, Denmark, 2600
    • GSK Investigational Site
  • Koebenhavn Oe, Denmark, 2100
    • GSK Investigational Site
• France
  • Lille, France, 59037
    • GSK Investigational Site
  • Limoges, France, 87042
    • GSK Investigational Site
  • Lyon, France, 69677
    • GSK Investigational Site
  • Nancy cedex, France, 54035
    • GSK Investigational Site
  • Rennes Cedex, France, 35033
    • GSK Investigational Site
  • Strasbourg Cedex, France, 67098
    • GSK Investigational Site
• Germany
  • Berlin, Germany, 13509
    • GSK Investigational Site
  • Baden-Wuerttemberg
    • Kehl-Kork, Baden-Wuerttemberg, Germany, 77694
      • GSK Investigational Site
    • Stuttgart, Baden-Wuerttemberg, Germany, 70372
      • GSK Investigational Site
    • Tuebingen, Baden-Wuerttemberg, Germany, 72076
      • GSK Investigational Site
  • Hessen
    • Marburg, Hessen, Germany, 35043
      • GSK Investigational Site
  • Nordrhein-Westfalen
    • Bielefeld, Nordrhein-Westfalen, Germany, 33617
      • GSK Investigational Site
    • Bonn, Nordrhein-Westfalen, Germany, 53105
      • GSK Investigational Site
  • Schleswig-Holstein
    • Kiel, Schleswig-Holstein, Germany, 24105
      • GSK Investigational Site
• Italy
  • Calabria
    • Reggio Calabria, Calabria, Italy, 89100
      • GSK Investigational Site
  • Emilia-Romagna
    • Bologna, Emilia-Romagna, Italy, 40139
      • GSK Investigational Site
  • Lazio
    • Roma, Lazio, Italy, 00163
      • GSK Investigational Site
    • Roma, Lazio, Italy, 00185
      • GSK Investigational Site
  • Liguria
    • Genova, Liguria, Italy, 16153
      • GSK Investigational Site
  • Marche
    • Torrette di Ancona, Marche, Italy, 60126
      • GSK Investigational Site
  • Puglia
    • Foggia, Puglia, Italy, 71100
      • GSK Investigational Site
  • Sicilia
    • Palermo, Sicilia, Italy, 90129
      • GSK Investigational Site
  • Toscana
    • Pisa, Toscana, Italy, 56126
      • GSK Investigational Site
    • Siena, Toscana, Italy, 53100
      • GSK Investigational Site
• Netherlands
  • Breda, Netherlands, 4818 CK
    • GSK Investigational Site
  • Den Haag, Netherlands, 2512 VA
    • GSK Investigational Site
  • Heemstede, Netherlands, 2103 SW
    • GSK Investigational Site
  • Heeze, Netherlands, 5591 VE
    • GSK Investigational Site
• Poland
  • Ilawa, Poland, 13-300
    • GSK Investigational Site
  • Katowice, Poland, 40-662
    • GSK Investigational Site
  • Krakow, Poland, 31-209 Krakow
    • GSK Investigational Site
  • Warszawa, Poland, 00-453
    • GSK Investigational Site
  • Warszawa, Poland, 02-952
    • GSK Investigational Site
• Russian Federation
  • Belgorod, Russian Federation, 308007
    • GSK Investigational Site
  • Kazan, Russian Federation, 420064
    • GSK Investigational Site
  • Krasnodar, Russian Federation, 350007
    • GSK Investigational Site
  • Moscow, Russian Federation, 117049
    • GSK Investigational Site
  • Moscow, Russian Federation, 107150
    • GSK Investigational Site
  • Samara, Russian Federation, 443095
    • GSK Investigational Site
  • Smolensk, Russian Federation, 214 019
    • GSK Investigational Site
  • St.-Petersburg, Russian Federation, 193019
    • GSK Investigational Site
• Spain
  • Madrid, Spain, 28046
    • GSK Investigational Site
  • Sevilla, Spain, 41009
    • GSK Investigational Site
  • Valencia, Spain, 46026
    • GSK Investigational Site
  • Vigo, Spain, 36204
    • GSK Investigational Site
• Thailand
  • Bangkok, Thailand, 10400
    • GSK Investigational Site
  • Khon Kaen, Thailand, 40002
    • GSK Investigational Site
  • Songkla, Thailand, 90110
    • GSK Investigational Site
• Ukraine
  • Dnepropetrovsk, Ukraine, 49005
    • GSK Investigational Site
  • Donetsk, Ukraine, 83037
    • GSK Investigational Site
  • Kharkiv, Ukraine, 61068
    • GSK Investigational Site
  • Lugansk, Ukraine, 91045
    • GSK Investigational Site
  • Lviv, Ukraine, 79010
    • GSK Investigational Site
  • Odesa, Ukraine, 65014
    • GSK Investigational Site
  • Oleksandrivka village, Odesa, Ukraine, 67513
    • GSK Investigational Site
  • Poltava, Ukraine
    • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Is 18 years of age (men or women)
• Has a confident diagnosis of epilepsy with partial-onset seizures i.e., simple or complex partial seizures with or without secondary generalization (International League Against Epilepsy (ILAE) classification; 1981) for more than 24 weeks prior to the start of Baseline phase.
• Has experienced at least 4 partial-onset seizures (i.e., simple or complex partial seizures with or without secondary generalization) during an 8-week (i.e., 56 days) prospective Baseline Phase with at least one partial seizure occurring during each 4 week (i.e., 28-day) period.
• Receiving a stable dose of one of the following AEDs: carbamazepine/oxcarbazepine, lamotrigine, levetiracetam or valproic acid. The AED dose must be stable 4 weeks prior to start of collection of baseline seizure data (retrospective or prospective) and during the Baseline period.
• Is able and willing to maintain an accurate and complete daily written seizure calendar and functional status diary or has a caregiver who is able and willing to do so for the entire duration of the study.
• Is able to comply with dosing of study drug, background AED and all study procedures.
• Has given written informed consent, or has a legally authorized representative who has given written informed consent, prior to the performance of any study assessments.
• A female subject is eligible to enter and participate in the study if she is either of non-childbearing potential or child-bearing potential but has a negative pregnancy test at Screening and agrees to satisfy one of the contraception methods as listed in the protocol, and is not pregnant or lactating or planning to become pregnant during the study.
• French subjects only: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Exclusion Criteria:

• Has a history of generalised epilepsy (e.g. Lennox-Gastaut, Juvenile Myoclonic etc.)
• Has had status epilepticus (other than simple partial status epilepticus) within the 24 weeks prior to Baseline Visit.
• Has participated in a previous retigabine study (subjects with documented evidence of having received placebo will be eligible).
• Is currently or has been abusing substance(s) or other medications in the 12 months prior to Baseline visit.
• Has taken an investigational drug, or used an investigational device, within the previous 30 days prior to screening or plans to take an investigational drug anytime during the study.
• Is currently following or planning to follow the ketogenic diet.
• Has been treated with vigabatrin within the past 6 months prior to collection of baseline seizure data.
• Is planning surgery or implantation of a Vagus Nerve Stimulator (VNS) to control seizures during the study.
• Is suffering from acute or progressive neurological disease, severe psychiatric disease, or severe mental abnormalities that are likely to interfere with the objectives of the study.
• Has any medical condition that, in the investigator's judgment, is considered to be clinically significant and could potentially affect subject safety or study outcome.
• Has a QTc ≥450 millisecond (msec) or greater than or equal to 480 msec for subjects with Bundle Branch Block at the time of screening.
• Has active suicidal plan/intent or has had active suicidal thoughts in the past 6 months. Has history of suicide attempt in the last 2 years or more than 1 lifetime suicide attempt.
• French Subjects: the French subject has participated in any study using an investigational drug during the previous 30 days or 5 half-lives (whichever is longer).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Retigabine IR; Open Label flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).	Drug: Retigabine IR; Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With a >=50% Reduction in Partial-onset Seizure (POS) Frequency From Baseline	The number of participants experiencing a >=50% reduction from Baseline (BL) in POS frequency during the Treatment Phase (TP) (i.e., Titration Phase and Flexible Dose Evaluation [FDE] Phase) was measured. A POS has its onset in a limited area on one side of the brain. POSs may remain limited or may spread to involve both sides of the brain. For both the Baseline Phase and the TP, seizure frequency was calculated as a 28-day rate using the following formula: 28 x {[(number of countable partial seizures in Phase) + (10 x number of days with innumerable seizures in Phase) + (number of occurrences of status epilepticus in Phase)] / number of applicable days in the Phase}, where all days in the Phase are considered applicable (including days with 0 seizures), except for days on which the participant failed to complete the Seizure Diary. >= 50% reduction from BL is calculated as 100 x (28-day partial seizure rate [PSR] for the TP - 28-day PSR for the BL Phase) / 28-day PSR for the BL Phase.	From Baseline through Week 20 (Day 140)/Early Withdrawal

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With the Indicated Reduction or Increase From Baseline in Partial-onset Seizure Frequency	Participants were assessed for the percent change from Baseline in seizure frequency; changes were categorized as Any Decrease (>0 to 25%, 25 to <50%, 50 to 75%, >75 to 100%) or No Change or Any Increase (>25%, 0 to 25%). A partial-onset seizure is a seizure that has its onset in a limited area on one side of the brain. Partial-onset seizures may remain limited or may spread to involve both sides of the brain.	From Baseline through Week 20 (Day 140)/Early Withdrawal
Number of Participants With a >=25%, >=75%, or 100% Reduction in Partial-onset Seizure Frequency From Baseline	The number of participants experiencing a >=25%, >=75%, and 100% reduction from Baseline in partial-onset seizure frequency during the Treatment Phase (TP) (i.e., Titration Phase and Flexible Dose Evaluation [FDE] Phase) was measured. A partial-onset seizure is a seizure that has its onset in a limited area on one side of the brain. Partial-onset seizures may remain limited or may spread to involve both sides of the brain.	From Baseline through Week 20 (Day 140)/Early Withdrawal
Percent Change From Baseline in Partial-onset Seizure Frequency	Percent change from Baseline was calculated as the difference in the partial-onset seizure frequency (Treatment Phase minus the Baseline Phase) divided by the Baseline Phase frequency, multiplied by 100. Negative values indicate reductions from Baseline. A partial-onset seizure is a seizure that has its onset in a limited area on one side of the brain. Partial-onset seizures may remain limited or may spread to involve both sides of the brain.	From Baseline through Week 20 (Day 140)/Early Withdrawal
Functional Status Diary (FSD): Percent Change From Baseline in Epilepsy-related Worry	Participants were asked the following question daily: "How would you rate your epilepsy-related worry over the last 24 hours?" The original possible responses were 0-10, with 0="No worry" and 10="Worst worry imaginable." However, in the summarization, "1" was added to each participant's daily response, changing the possible values to 1-11, so that there would be no possibility of the percent change from Baseline being undefined. Baseline and Treatment Phase averages were calculated for each participant. The denominators for these by-phase averages were the number of non-missing days for each variable and phase. The by-phase averages were used as follows in the calculation of percent change from Baseline for each participant: 100 x Treatment Phase average - Baseline Phase average) / Baseline Phase average. A negative percent change from Baseline indicates a reduction from Baseline.	Baseline through Week 20/Early Withdrawal
Functional Status Diary (FSD): Percent Change From Baseline in Epilepsy-related Limitation of Ability to do What You Needed to	Participants were asked the following question daily: "How would you rate the extent to which epilepsy limited your ability to do what you needed to do over the last 24 hours?" The original possible responses were 0-10, with 0="Not at all limited" and 10="Unable to do anything I needed to." However, in the summarization, "1" was added to each participant's daily response, changing the possible values to 1-11, so that there would be no possibility of the percent change from Baseline being undefined. Baseline and Treatment Phase averages were calculated for each participant. The denominators for these by-phase averages were the number of non-missing days for each variable and phase. The by-phase averages were used as follows in the calculation of percent change from Baseline for each participant: 100 x Treatment Phase average - Baseline Phase average) / Baseline Phase average. A negative percent change from Baseline indicates a reduction from Baseline.	Baseline through Week 20/Early Withdrawal
Functional Status Diary (FSD): Percent Change From Baseline in Epilepsy-related Limitation of Ability to do What You Wanted to	Participants were asked the following question daily: "How would you rate the extent to which epilepsy limited your ability to do what you wanted to do over the last 24 hours?" The original possible responses were 0-10, with 0="Not at all limited" and 10="Unable to do anything I wanted to." However, in the summarization, "1" was added to each participant's daily response, changing the possible values to 1-11, so that there would be no possibility of the percent change from Baseline being undefined. Baseline and Treatment Phase averages were calculated for each participant. The denominators for these by-phase averages were the number of non-missing days for each variable and phase. The by-phase averages were used as follows in the calculation of percent change from Baseline for each participant: 100 x Treatment Phase average - Baseline Phase average) / Baseline Phase average. A negative percent change from Baseline indicates a reduction from Baseline.	Baseline through Week 20/Early Withdrawal
Percent Change From Baseline in Functional Status: Percentage of Days With no Missed Work or School Time	Participants were asked the following question daily: "Did you miss any time from work or school in the last 24 hours due to epilepsy?" Possible responses were Yes, No, and NA=Not Applicable (no planned work or school in the last 24 hours). The variable summarized is the percentage of days with no missed work or school. Baseline and Treatment Phase averages were calculated for each participant. The denominators for these by-phase averages were the number of non-missing days for each variable and phase. The by-phase averages were used as follows in the calculation of percent change from Baseline for each participant: 100 x Treatment Phase average - Baseline Phase average) / Baseline Phase average. A positive percent change from Baseline indicates a reduction from Baseline in missed work or school.	Baseline through Week 20/Early Withdrawal
Change From Baseline in the Short Form 36 Health Survey, Version 2 (SF-36v2) Domain Scores at Week 20/Early Withdrawal	The SF-36v2 health survey is a self-administered, generic, 36-item questionnaire designed to measure 8 domains of functional health status and well-being: physical functioning, role-physical, bodily pain, general health perceptions, vitality, social functioning, role-emotional, and mental health. Each domain is scored from 0 (poorer health) to 100 (better health). Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Positive changes from Baseline indicate improvement.	Baseline through Week 20/Early Withdrawal
Change From Baseline in the SF-36v2 Physical Component Summary Score at Week 20/Early Withdrawal	The SF-36 v2 Health Survey is a self-administered, generic, 36-item questionnaire designed to measure 8 domains of functional health status and well-being: physical functioning, role-physical, bodily pain, general health perceptions, vitality, social functioning, role-emotional, and mental health. Each domain is scored from 0 (poorer health) to 100 (better health).The physical component summary (PCS) score is a summary score representing overall physical health, which is derived from the 8 domains. As with the domains, PCS scores range from 0 to 100; higher scores represent better health. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Positive changes from Baseline indicate improvement.	Baseline through Week 20/Early Withdrawal
Change From Baseline in the SF-36v2 Mental Component Summary Score at Week 20/Early Withdrawal	The SF-36 v2 Health Survey is a self-administered, generic, 36-item questionnaire designed to measure 8 domains of functional health status and well-being: physical functioning, role-physical, bodily pain, general health perceptions, vitality, social functioning, role-emotional, and mental health. Each domain is scored from 0 (poorer health) to 100 (better health).The mental component summary (MCS) score is a summary score representing overall mental health, which is derived from the 8 domains. As with the domains, MCS scores range from 0 to 100; higher scores represent better health. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Positive changes from Baseline indicate improvement.	Baseline through Week 20/Early Withdrawal
Number of Participants With the Indicated Response for the Epilepsy-related Worry Component of the Patient Global Impression of Change (PGI-C) Score	The PGI-C questionnaire was to be completed by the participant. Participants were asked the following question: Compared to before you started this study, how would you rate your current epilepsy-related worry: Much better, Moderately better, A little better, Unchanged, A little worse, Moderately worse, Much worse?	Baseline through Week 20/Early Withdrawal
Change From Baseline in the PGI-C Score: Epilepsy-related Worry	The PGI-C questionnaire was to be completed by the participant. Participants were asked the following question: Compared to before you started this study, how would you rate your current epilepsy-related worry: Much better, Moderately better, A little better, Unchanged, A little worse, Moderately worse, Much worse? Rating scores are integers from 1 to 7, with 1=Much better and 7=Much worse.	Baseline through Week 20/Early Withdrawal
Number of Participants With the Indicated Response for the Current Ability to do the Things You Need to do Component of the PGI-C Score	The PGI-C questionnaire was to be completed by the participant. Participants were asked the following question: Compared to before you started this study, how would you rate your current ability to do the things you need to do: Much better, Moderately better, A little better, Unchanged, A little worse, Moderately worse, Much worse?	Baseline through Week 20/Early Withdrawal
Change From Baseline in the PGI-C Score: Current Ability to do the Things You Need to do	The PGI-C questionnaire was to be completed by the participant. Participants were asked the following question: Compared to before you started this study, how would you rate your current ability to do the things you need to do: Much better, Moderately better, A little better, Unchanged, A little worse, Moderately worse, Much worse? Rating scores are integers from 1 to 7, with 1=Much better and 7=Much worse.	Baseline through Week 20/Early Withdrawal
Number of Participants With the Indicated Response for the Current Ability to do the Things You Want to do Component of the PGI-C Score	The PGI-C questionnaire was to be completed by the participant. Participants were asked the following question: Compared to before you started this study, how would you rate your current ability to do the things you want to do: Much better, Moderately better, A little better, Unchanged, A little worse, Moderately worse, Much worse.	Baseline through Week 20/Early Withdrawal
Change From Baseline in the PGI-C Score: Current Ability to do the Things You Want to do	The PGI-C questionnaire was to be completed by the participant. Participants were asked the following question: Compared to before you started this study, how would you rate your current ability to do the things you want to do: Much better, Moderately better, A little better, Unchanged, A little worse, Moderately worse, Much worse? Rating scores are integers from 1 to 7, with 1=Much better and 7=Much worse.	Baseline through Week 20/Early Withdrawal

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Study record dates

Study Major Dates

• Study Start: July 1, 2010
• Primary Completion (Actual): December 1, 2012
• Study Completion (Actual): December 1, 2012

Study Registration Dates

• First Submitted: July 16, 2010
• First Submitted That Met QC Criteria: October 21, 2010
• First Posted (Estimate): October 25, 2010

Study Record Updates

• Last Update Posted (Estimate): October 17, 2014
• Last Update Submitted That Met QC Criteria: October 9, 2014
• Last Verified: October 1, 2014

More Information

Terms related to this study

• Keywords: Epilepsy; Seizures; GW582892; Partial-onset seizures; retigabine IR; Open label, flexible dose
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurologic Manifestations; Epilepsy; Seizures; Molecular Mechanisms of Pharmacological Action; Membrane Transport Modulators; Anticonvulsants; Ezogabine
• Other Study ID Numbers: 113905